- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 29, 2024Robins Kaplan Mourns Death of New York Associate Waleed Abbasi
-
April 29, 2024Robins Kaplan Secures $7.75 Million Verdict in Aerosol Dust Remover Abuse Case
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
May 20, 2024The Present and Future of DEI
-
May 23, 202414th Annual Disability Justice Seminar
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Abbreviated New Drug Applications and 505(b)(2) Applications
Second Quarter
This Generic Launches chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
Reference Listed Drug | ANDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Noxafil | Merck | posaconazole | Hikma | Used to prevent serious fungal infections that can spread throughout the body in adults and children 2 years of age and older with a weakened ability to fight infection | 4/3/2023 |
Prolixin | Apothecon | fluphenazine | Upsher Smith | Used to treat schizophrenia and psychotic symptoms such as hallucinations, delusions, and hostility | 4/3/2023 |
Noxafil | Merck | posaconazole | Endo | Used to prevent serious fungal infections that can spread throughout the body in adults and children 2 years of age and older with a weakened ability to fight infection | 4/4/2023 |
Bentyl | AbbVie | dicyclomine | TWi | Used to treat functional bowel disorder and irritable bowel syndrome | 4/2023? |
K-Tab | AbbVie | potassium chloride | TWi | Used for prophylaxis and treatment of hypokalemia in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient | 4/2023? |
Combigan | AbbVie | brimonidine / timolol | Upsher Smith | Used to treat increased pressure in the eye caused by glaucoma or a condition called hypertension of the eye | 4/13/2023 |
Depo-Testosterone | Pfizer | testoterone cypionate | Xiromed | Used as replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone | 4/13/2023 |
Argatroban | Novartis | argatroban | Par / Endo | Used for prophylaxis or treatment of thrombosis in adult patients with heparin- induced thrombocytopenia (HIT) | 4/17/2023 |
Lexiscan | Astellas | regadenoson | Hikma | Is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress | 4/17/2023 |
Daliresp | AstraZeneca | roflumilast | Camber / Hetero | Used to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations | 4/21/2023 |
Remodulin | United Therapeutics | treprostinil | Dr. Reddy's Labs | Used to treat pulmonary arterial hypertension (PAH) | 4/21/2023 |
Zyflo CR | Chiesi | zileuton | Camber / Hetero | Is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older | 4/26/2023 |
Delestrogen | Par | estradiol valerate | Xiromed | Used to treat moderate to severe vasomotor symptoms associated with the menopause | 5/1/2023 |
Phernegan | Mylan | promethazine | Camber / Hetero | Used to treat allergy symptoms such as itching, runny nose, sneezing, itchy or watery eyes, hives, and itchy skin rashes; also prevents motion sickness, and treats nausea and vomiting or pain after surgery; also used as a sedative or sleep aid | 5/3/2023 |
Lexiscan | Astellas | regadenoson | Dr. Reddy's Labs | Is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress | 5/5/2023 |
Syprine | Bausch | trientine HCl | Camber / Hetero | Used to treat patients with Wilson’s disease who are intolerant of penicillamine | 5/8/2023 |
Cystadane | Recordati | betaine anhydrous | Eton | Used to treat homocystinuria | 5/10/2023 |
Prezista | Johnson & Johnson | darunavir | Teva | Used to treat human immunodeficiency virus (HIV) in children age 3 or above and adults with HIV-1 infection | 6/1/2023 |
Prezista | Johnson & Johnson | darunavir | Lupin | Used to treat human immunodeficiency virus (HIV) in children age 3 or above and adults with HIV-1 infection | 6/3/2023 |
Mexitil | Boehringer Ingelheim | mexiletine HCl | Camber / Hetero | Used to treat documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening | 6/6/2023 |
Iressa | AstraZeneca | gefitinib | Apotex | Used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK | 6/14/2023 |
Treanda | Teva | bendamustine | Apotex | Used to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen | 6/14/2023 |
Vasostrict | Endo | vasopressin | Fresenius Kabi | Used to treat increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines | 6/14/2023 |
Vimpat | UCB | lacosamide | Apotex | Used to treat partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older | 6/14/2023 |
Dexilant | Takeda | dexlansoprazole | Par / Endo | Used to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) | 6/15/2023 |
Thiamine | Fresenius Kabi | thiamine HCl | Lupin | Used to treat thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety | 6/19/2023 |
Iressa | AstraZeneca | gefitinib | Teva | Used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK | 6/21/2023 |
Banzel | Eisai | rufinamide | Lupin | Used for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in pediatric patients one year of age and older and adults | 6/23/2023 |
Kinevac | Bracco Diagnostics | sincalide | Fresenius Kabi | Used to stimulate gallbladder contraction or pancreatic secretion during diagnostic tests, and accelerate fluoroscopy and x-ray examination of the intestinal tract | 6/21/2023 |
Vancocin | ANI | vancomycin | Amneal | Used to treat serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci; also indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs | 6/2023? |
Noxafil | Merck | posaconazole | Endo / Par | Indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia (low white blood cell counts) from chemotherapy. | 6/29/2023 |
Midazolam | Inforlife | Midazolam in 0.9% sodium chloride | Hikma | Used for continuous intravenous infusion for sedation of intubated and mechanically ventilated adult, pediatric, and neonatal patients as a component of anesthesia or during treatment in a critical care setting | 6/30/2023 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.